NFKB1 and hepatocellular carcinoma: Berberine’s dual targeting of DNA (via topoisomerase inhibition) and inflammation (via NF-κB suppression) highlights a possible synergistic mechanism in hepatocellular carcinoma management that may help overcome drug resistance, though this requires direct experimental validation.